Alexandr Serhiyenko

Prof. Dr. Alexandr Serhiyenko

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2022 in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Verified
Journal Article
Open access
PDF file
ASAlexandr Serhiyenko
Alexandr Serhiyenko
ASAlexandr Serhiyenko
Alexandr Serhiyenko
Congestive heart failure (CHF) is the final stage of cardiovascular disease and one of the leading causes of death. CHF develops in patients with the chronic coronary syndrome, hypertension, myocarditis, endocarditis, pericarditis, and other diseases. The prevalence of CHF in recent years is growing steadily and is about 2% in the adult population. Among the factors that worsen the prognosis of CHF is diabetes mellitus (DM). Type 2 DM is an independent risk factor for heart failure (HF), and fasting plasma glucose and increased glycated hemoglobin A1c are significantly associated with an increased risk of HF. This review article summarizes the existing literature on the current state of the problem of DM and CHF. In particular, there are considered the issues related to the features of myocardial damage in type 2 DM, DM as a risk factor for HF, subclinical myocardial disorders in diabetic patients, HF as a risk factor for DM; pathophysiological features of DM and HF; classification of CHF (according to the New York Heart Association, the American College of Cardiology Foundation/American Heart Association, the European Society of Cardiology); diagnosis of CHF with preserved, reduced and mildly reduced left ventricular ejection fraction; principles of pathogenetic therapy of HF in DM, in particular, the appointment of drugs that affect the renin-angiotensin-aldosterone system (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers); sacubitril/valsartan; beta-adrenergic receptor blockers, mineralocorticoid receptor antagonists, sinus node inhibitors, sodium-glucose cotransporter type 2 inhibitors, diuretics. Treatment of a patient with DM and HF will be successful only if adequate and safe antidiabetic therapy is prescribed, on the one hand, and metabolically neutral pharmacological therapy, on the other.

19 June 2024 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Open access
PDF file
ASAlexandr Serhiyenko
Alexandr Serhiyenko
MBMyroslav Baitsar
Myroslav Baitsar
VSVolodymyr Sehin
Volodymyr Sehin
LSLudmila Serhiyenko
Ludmila Serhiyenko
VKVitaliy Kuznets
Vitaliy Kuznets
ASAlexandr Serhiyenko
Alexandr Serhiyenko
This narrative review was aimed to analyze the scientific data about the association of post-traumatic stress disorder, insomnia, obstructive sleep apnea syndrome, dyssomnias, heart rate variability, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular autonomic neuropathy, along with potential pathophysiological mechanisms underlying these associations. The results of experimental, cohort, prospective, and randomized clinical studies provide evidence of common pathogenetic pathways contributing to their development. Searches were conducted in Scopus, Science Direct (from Elsevier), EBSCO, and PubMed databases, including the Medline databases. Additionally, a manual search of publication bibliographies was undertaken to uncover research outcomes not accessible through online searches.

1 January 2022 in Vessel Plus
Verified
Journal Article
Open access
PDF file
ASAlexandr Serhiyenko
Alexandr Serhiyenko
ASAlexandr A. Serhiyenko
Alexandr A. Serhiyenko
VSVolodymyr B. Segin
Volodymyr B. Segin
LSLudmila M. Serhiyenko
Ludmila M. Serhiyenko
Aim: To investigate the changes of insulin resistance (IR), parameters of arterial stiffness, concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), and echocardiographic parameters in patients with cardiac autonomic neuropathy (CAN) and type 2 diabetes mellitus (T2D). Methods: This study recruited 44 patients with T2D (19 patients without CAN and 25 patients with CAN) and 15 healthy volunteers. Arterial stiffness, immunoreactive insulin, homeostasis model assessment IR, NT-proBNP parameters, and echocardiographic examination were assessed. Results: Development of CAN is associated with increase in NT-proBNP levels, IR parameters, and arterial stiffening. Among patients with CAN, arterial stiffness parameters were considered as high. We found out that among patients of this group, the value of brachial augmentation index was normal in 52%, elevated in 40%, and pathological in 8%; pulse wave velocity was normal in 16%, elevated in 52%, and pathological in 32% of cases. Obtained results showed that development of CAN is accompanied by more pronounced left ventricular diastolic dysfunction and by formation of left ventricular hypertrophy (LVH), mostly by concentric type. Among patients of this group concentric LVH was diagnosed among 76 % and eccentric LVH among 16% of persons. Multiple regression analysis, after controlling for age, sex, diabetes duration, blood pressure, HbA1c, and left ventricular mass index, showed an independent association of heart rate response to deep breathing with pulse wave velocity (P < 0.001). Conclusion: Development of CAN is associated with increased IR parameters, increased levels of NT-proBNP, arterial stiffening, left ventricular diastolic dysfunction, and formation of LVH, mostly by concentric type.

28 December 2023 in Endokrynologia
Verified
Journal Article
Open access
PDF file
ASAlexandr Serhiyenko
Alexandr Serhiyenko
VSV.B. Sehin
V.B. Sehin
LSL.M. Serhiyenko
L.M. Serhiyenko
ASA.A. Serhiyenko
A.A. Serhiyenko
Патофізіологічні особливості взаємозв’язків між посттравматичним стресовим розладом (ПТСР) і метаболічнимсиндромом (МС) залишаються активною галуззю досліджень. Вплив травматичних життєвих подій має серйозні нега-тивні наслідки для функціонування фізіологічних систем, зокрема, ендокринної та вегетативної нервової системи (ВНС).Дисрегуляція ВНС може пов’язувати патофізіологічні та психологічні особливості ПТСР. Зокрема, порушення функціону-вання ВНС спостерігаються при різних психологічних розладах, зокрема ПТСР. Останнім часом значна увага приділяєть-ся пошуку і з’ясуванню особливостей взаємозв’язків між метаболічними дисфункціями та психічними розладами, зокре-ма ПТСР, який може становити групу ризику МС. ПТСР і МС можуть мати схожі біологічні механізми, що лежать в їх основі.Ймовірно, що зміни запальної та нейроендокринної систем пов’язані з ПТСР. Однак, незрозуміло, чи є ці зв’язки причин-но-наслідковими. Крім того, біологічні та поведінкові механізми, що лежать в основі цих асоціацій, недостатньо вивчені.Правдоподібною є гіпотеза, що дисфункціональна індивідуальна адаптація до стресу може підвищувати вразливість дометаболічних дисфункцій, які, своєю чергою, здатні сприяти виникненню психопатологічних змін у посттравматичнийперіод. Підхід до ПТСР і МС як до системних станів, що включають дисфункцію гіпоталамо-гіпофізарно-адреналової вісі(ГГАВ), хронічного запалення низької інтенсивності (ХЗНІ), інсулінової резистентності (ІР), симпато-адреналової системи,інших метаболічних порушень і зміни ВНС, а також значний психологічний тягар, має важливі наслідки з точки зору ме-дичних проблем та прогнозу захворювання. Необхідні подальші дослідження для тестування нових методів діагностики,спрямованих на нейроендокринну та імуно-метаболічну системи. Цей огляд має на меті обговорити значення й осо-бливості ПТСР і МС. Особлива увага приділена опису наявних доказів епідеміологічних, експериментальних і клінічнихвипробувань щодо їх взаємозв’язків. Розглянуті питання спільних патогенетичних ланок ПТСР і МС, зокрема, значенняпорушень функціонування ГГАВ, ХЗНІ, ІР, симпато-адреналової системи та ВНС.

3 March 2024 in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Verified
Journal Article
Open access
PDF file
ASAlexandr Serhiyenko
Alexandr Serhiyenko
VSV.B. Sehin
V.B. Sehin
VPVolodymyr Pankiv
Volodymyr Pankiv
ASAlexandr Serhiyenko
Alexandr Serhiyenko
Post-traumatic stress disorder (PTSD) and metabolic syndrome (MetS) frequently coexist and share neurobiological and clinical features. In particular, the results of meta-analyses indicate a higher prevalence of MetS in patients with PTSD compared to the general population. PTSD is also a recognized risk factor for MetS. This synchronicity can be partially explained by pathogenetic pathways present in both conditions. These include genetic factors, dysfunction of the hypothalamic-pituitary-adrenal axis, chronic low-grade inflammation, oxidative stress, insulin resistance, and immune dysregulation. Thus, similar mechanisms are involved in the clinical worsening of PTSD and the development of adverse cardiovascular events associated with MetS. Dyssomnias are one of the characteristic clinical features of PTSD. Today, it is believed that posttraumatic circadian rhythm disorders are the core and not a secondary feature of PTSD, which mediate the neurobiological correlates of disorders due to homeostasis imbalance. At the same time, dyssomnias, chronodestruction, and depressive disorders are part of the pathogenesis of insulin resistance, obesity, and MetS. Thus, treatment of dyssomnias is one of the key tasks in the prevention and treatment of comorbid PTSD and MetS. Regulation of sleep processes and circadian rhythms through exogenous intervention, especially with melatonergic drugs, is likely to be a key part of preventing and treating dyssomnias in people who have both PTSD and MetS. The purpose of this review is to analyze the specifics of the relationships between PTSD and MetS, PTSD and dyssomnias, MetS and sleep disorders. We conducted the search in Scopus, Science Direct (from Elsevier), and PubMed, including Medline databases. The key words used were “post-traumatic stress disorder,” “dyssomnias,” “chronodestruction,” and “metabolic syndrome”. The identification of research findings that were not found during online searches involved manual searching of the bibliography of publications.

1 October 2022 in Endocrine Regulations
Verified
Journal Article
Open access
PDF file
ASAlexandr Serhiyenko
Alexandr Serhiyenko
LSLudmila M. Serhiyenko
Ludmila M. Serhiyenko
VSVolodymyr B. Sehin
Volodymyr B. Sehin
ASAlexandr A. Serhiyenko
Alexandr A. Serhiyenko
Several cross-sectional trials have revealed increased arterial stiffness connected with the cardiac autonomic neuropathy in types 2 and 1 diabetic patients. The pathophysiological relationship between arterial stiffness and autonomic dysfunction in diabetes mellitus is still underinvestigated and the question whether the presence of cardiac autonomic neuropathy leads to arterial stiffening or increased arterial stiffness induced autonomic nervous system impairment is still open. Both arterial stiffness and dysfunction of the autonomic nervous system have common pathogenetic pathways, counting state of the chronic hyperinsulinemia and hyperglycemia, increased formation of advanced glycation end products, activation of protein kinase C, development of endothelial dysfunction, and chronic low-grade inflammation. Baroreceptor dysfunction is thought to be one of the possible reasons for the arterial wall stiffening development and progression. On the contrary, violated autonomic nervous system function can affect the vascular tone and by this way alter the large arteries walls elastic properties. Another possible mechanism of attachment and/or development of arterial stiffness is the increased heart rate and autonomic dysfunction corresponding progression. This minireview analyzes the current state of the relationship between the diabetes mellitus and the arterial stiffness. Particular attention is paid to the analysis, interpretation, and application of the results obtained in patients with type 2 diabetes mellitus and diabetic cardiac autonomic neuropathy.